GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Beam Therapeutics BEAM · USD

Health Care · US listing · 🇺🇸 United States

Compare

27.02

+2.31%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$139.7m

FY2017FY2025

Net income

−$80.0m

FY2017FY2025

Free cash flow

−$360.0m

FY2017FY2025

Shareholders' equity

$1.24bn

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue$139.7m$63.5m$377.7m$60.9m$51.8m$24,000$18,000——
Research and development$409.6m$367.6m$437.4m$311.6m$387.1m$103.2m$54.6m$33.9m$5.9m
Operating income−$383.7m−$415.6m−$176.5m−$338.5m−$392.5m−$132.8m−$75.2m−$45.7m−$8.6m
Net income−$80.0m−$376.7m−$132.5m−$289.1m−$370.6m−$194.6m−$78.3m−$115.3m−$8.7m
Diluted earnings per share-0.76-4.55-1.60-4.08-5.45-3.23-2.55-3.28-0.67

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$1.48bn$1.10bn$1.46bn$1.34bn$1.47bn$451.7m$156.1m$167.0m$2.4m
Cash and short-term investments$1.25bn$850.7m$1.19bn$1.08bn$965.6m$299.7m$91.8m$146.4m$1.9m
Total liabilities$242.8m$370.3m$478.4m$608.2m$647.7m$206.1m$55.2m$33.0m$6.6m
Debt——$484,000$3.0m$5.3m$7.4m$5.7m$13.8m—
Shareholders' equity$1.24bn$733.5m$981.3m$733.5m$826.7m$245.6m$100.9m$134.0m−$4.2m
Shares outstanding105m83m83m71m68m60m31m35m13m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$345.1m−$347.2m−$149.2m$22.5m−$66.3m−$95.7m−$72.0m−$20.3m−$2.7m
Capital spending−$14.9m−$8.9m−$33.7m−$49.0m−$46.8m−$16.4m−$12.5m−$13.1m−$346,000
Free cash flow−$360.0m−$356.2m−$182.9m−$26.4m−$113.1m−$112.1m−$84.5m−$33.4m−$3.1m
Dividends paid——————−$12.7m——

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$490,000$31.7m$114.1m$9.7m$8.5m$7.5m$30.1m$14.3m
Operating income−$126.6m−$107.2m−$17.4m−$126.8m−$120.2m−$119.3m−$100.0m−$106.5m
Net income−$122.7m−$94.3m$244.3m−$112.7m−$102.3m−$109.3m−$90.4m−$96.7m
Diluted earnings per share-1.18-0.902.33-1.07-0.97-1.04-1.09-1.17
Cash from operations−$66.0m−$128.0m−$83.0m−$81.0m−$76.0m−$103.0m−$76.0m−$88.0m
Capital spending−$2.0m−$2.0m−$3.0m−$5.0m−$3.0m−$3.0m−$2.0m−$1.0m
Free cash flow−$68.0m−$130.0m−$86.0m−$86.0m−$79.0m−$106.0m−$78.0m−$89.0m
Total assets$1.39bn$1.48bn$1.48bn$1.31bn$1.39bn$1.47bn$1.10bn$1.17bn
Cash and short-term investments$1.15bn$1.21bn$1.25bn$1.07bn$1.15bn$1.22bn$850.7m$925.8m
Debt$115.5m$115.0m$14.4m$12.7m$12.9m$13.2m$13.5m$12.9m
Shareholders' equity$1.07bn$1.16bn$1.24bn$966.0m$1.05bn$1.12bn$733.5m$791.3m

Financial ratios

Data as of 27 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-25.9%-593.1%-34.7%-468.9%-458.1%-553166.7%
Net margin-57.2%-593.1%-35.1%-474.5%-714.9%-810800.0%
Return on equity-6.5%-51.4%-13.5%-39.4%-44.8%-79.2%
Return on assets-5.4%-34.1%-9.1%-21.5%-25.1%-43.1%
Free cash flow yield-13.2%-17.3%-5.9%4.2%-1.2%-5.5%
Revenue growth120.0%-83.2%520.0%17.5%215916.7%33.3%
Earnings growth-78.8%184.3%-54.2%-22.0%90.5%148.4%
Current ratio13.09x4.82x5.89x4.89x5.96x3.01x
Debt to equity0.01x0.02x0.01x0.01x0.02x0.05x
Equity ratio83.6%66.5%67.2%54.7%56.1%54.4%
Interest coverage-0.83x-7.67x-2.81x-18.68x-26390.22x-84.67x
R&D as a share of sales293.1%578.7%115.8%511.5%746.6%429912.5%
Buybacks as a share of market value-27.5%0.5%-16.8%-4.1%-12.9%-96.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue31.9%466.3%—
Operating income4.3%23.6%—
Net income-34.8%-16.3%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-36.4-5.5-17.0-9.6-14.6-25.3
Price to sales20.832.36.045.4104.5—

Market value over time

28 Feb 2020 to 26 Oct 2026, in USD

$134.9m$2.48bn

Share price return

Finished calendar years

202520242023202220212020
Return-1%-10%-26%-52%-7%375%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 4 Feb 2014.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.